Who
Briggs Morrison
Director
Company insider
Files Form 4 as: Director, Arvinas; Director, CRISPR Therapeutics AG; Director, Werewolf Therapeutics; Director, Carisma Therapeutics; Director, Repare Therapeutics; President, Head of R&D, Syndax Pharmaceuticals; Director, Codiak BioSciences; Director, NextCure.
In numbers
- Trades disclosed
- 141
- Buys
- 9
- Sells
- 23
- Bought
- $1.4M
- Sold
- $28.8M
- Companies
- 8
- Companies where not an officer
- 7
- First trade
- 6 Feb 2017
- Last trade
- 24 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 26 Jun 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —15,527 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,714 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,714 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —15,527 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 6 Mar 2026filed 9 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Bought | $268K20,000 at $13.40 | filing |
| 6 Mar 2026filed 9 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Bought | $268K20,000 at $13.40 | filing |
| 22 Sep 2025filed 24 Sep 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Bought | $227K30,000 at $7.57 | filing |
| 25 Jun 2025filed 27 Jun 2025 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,105 at $0.00 | filing |
| 25 Jun 2025filed 27 Jun 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —16,025 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | HOWL Werewolf Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 26 Jun 2024filed 27 Jun 2024 | Carisma Therapeuticsoption or derivative | SEC FORM 4 Code A | —19,350 at $0.00 | filing |
| 17 Jun 2024filed 20 Jun 2024 | Repare Therapeuticsoption or derivative | SEC FORM 4 Code A | —27,200 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,070 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —5,899 at $0.00 | filing |
| 24 May 2024filed 24 May 2024 | HOWL Werewolf Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 7 Feb 2024filed 9 Feb 2024 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 9 Aug 2023filed 10 Aug 2023 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —52,855 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.